Illustrative image – not actual.Biocon has chalked out investment plan for insulin programmes to be implemented by 2015.
The company has earmarked Rs 450 crore for the purpose. Of the total, it will invest Rs 100 crore on a dedicated research and development facility in Bengaluru, Rs 200 crore more on the ongoing research activity.
Biocon's first insulin product out of Pfizer's business deal with Biocon will hit the Indian market during FY12. The product will be available in India, followed by other emerging markets.
